Efficacy of cognitive enhancers for Alzheimer’s disease: protocol for a systematic review and network meta-analysis

BACKGROUND: Approximately 35 million people world-wide have Alzheimer’s disease and this is projected to nearly double by 2030. Cognitive enhancers, including cholinesterase inhibitors (for example, donepezil, galantamine and rivastigmine) and memantine (N-methyl-D-aspartic acid (NMDA) receptor anta...

Descripción completa

Detalles Bibliográficos
Autores principales: Tricco, Andrea C, vanderVaart, Sondra, Soobiah, Charlene, Lillie, Erin, Perrier, Laure, Chen, Maggie H, Hemmelgarn, Brenda, Majumdar, Sumit R, Straus, Sharon E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3407718/
https://www.ncbi.nlm.nih.gov/pubmed/22742585
http://dx.doi.org/10.1186/2046-4053-1-31

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3407718/
https://www.ncbi.nlm.nih.gov/pubmed/22742585
http://dx.doi.org/10.1186/2046-4053-1-31

Ejemplares similares